Morgan Stanley upgraded Quest Diagnostics (DGX) to Overweight from Equal Weight with a price target of $172, up from $145. The firm sees “incremental clarity” into Quest’s medium and longer term outlook and growth entering 2025 against the backdrop of a “seemingly lasting robust” utilization environment. Th9e company also has relative insulation from a negative election impact, the analyst tells investors in a research note. With the healthcare sector broadly commenting on persisting robust utilization trends, Quest Diagnostics should continue to be a beneficiary into 2025, contends Morgan Stanley.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $182 from $179 at BofA
- Quest Diagnostics assumed with a Buy at Jefferies
- Quest Diagnostics management to meet with Piper Sandler
- Quest Diagnostics price target raised to $165 from $150 at Piper Sandler
- Quest Diagnostics price target raised to $175 from $163 at Argus